Michael C Heinrich Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

4/2011	Survey of activated FLT3 signaling in leukemia.
3/2010	Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
5/2009	Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
5/2008	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
2/2008	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
7/2007	A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
12/2006	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
11/2006	Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
7/2006	Activating alleles of JAK3 in acute megakaryoblastic leukemia.
11/2005	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael C Heinrich Research Topics

Disease

87	Neoplasms (Cancer) 01/2022 - 01/2002
73	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2022 - 03/2002
21	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2011 - 03/2002
12	Disease Progression 10/2022 - 02/2005
9	Melanoma (Melanoma, Malignant) 01/2022 - 09/2003
9	Leukemia 12/2019 - 11/2004
9	Systemic Mastocytosis 11/2017 - 12/2004
7	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2004
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2020 - 03/2002
6	Fatigue 10/2020 - 08/2002
5	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2007
5	Nausea 10/2020 - 11/2003
4	Diarrhea 10/2020 - 08/2002
3	Dermatofibrosarcoma 05/2008 - 02/2005
3	Myeloproliferative Disorders (Myeloproliferative Disorder) 05/2008 - 10/2005
3	Seminoma 01/2006 - 03/2002
2	Anemia 11/2021 - 03/2004
2	Hypertension (High Blood Pressure) 01/2020 - 10/2012
2	Philadelphia Chromosome 12/2019 - 10/2019
2	Brain Neoplasms (Brain Tumor) 05/2015 - 10/2008
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2011 - 11/2005
2	Carcinogenesis 04/2010 - 09/2004
2	Breast Neoplasms (Breast Cancer) 04/2010 - 01/2010
2	Aggressive Fibromatosis (Desmoid) 05/2008 - 03/2006
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2006 - 10/2005
2	Mastocytosis 11/2006 - 03/2002
1	Pneumonia (Pneumonitis) 01/2022
1	Pulmonary Embolism 01/2022
1	Abdominal Pain (Pain, Abdominal) 11/2021
1	Constipation 10/2020
1	Alopecia (Baldness) 10/2020
1	Myalgia 10/2020
1	Dehydration (Water Stress) 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Pancreatitis 12/2019
1	Injection Site Reaction 01/2016
1	Spasm (Spasms) 01/2016
1	Vomiting 01/2016
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2016

Drug/Important Bio-Agent (IBA)

63	Imatinib Mesylate (Gleevec)FDA Link 05/2022 - 01/2002
43	Phosphotransferases (Kinase)IBA 03/2021 - 03/2002
20	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 05/2002
19	Tyrosine Kinase InhibitorsIBA 05/2022 - 03/2002
18	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2021 - 05/2002
15	Tyrosine (L-Tyrosine)FDA Link 03/2021 - 05/2002
11	Pharmaceutical PreparationsIBA 01/2022 - 05/2003
11	Sunitinib (Sutent)FDA Link 01/2020 - 05/2003
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 03/2002
8	Proteins (Proteins, Gene)FDA Link 03/2018 - 07/2002
7	ripretinibIBA 12/2021 - 01/2019
5	avapritinibIBA 10/2021 - 11/2017
4	ponatinibIBA 01/2022 - 11/2014
4	regorafenibIBA 10/2021 - 07/2012
4	Oncogene Proteins (Oncogene Protein)IBA 10/2020 - 01/2003
4	Biological ProductsIBA 12/2016 - 05/2002
4	DNA (Deoxyribonucleic Acid)IBA 03/2014 - 07/2004
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2012
3	Succinate Dehydrogenase (Fumarate Reductase)IBA 01/2022 - 09/2014
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 01/2007
3	Codon (Codons)IBA 11/2017 - 07/2004
3	ParaffinIBA 04/2010 - 07/2004
3	tandutinibIBA 08/2009 - 11/2004
3	Protein Isoforms (Isoforms)IBA 01/2006 - 12/2003
3	fms-Like Tyrosine Kinase 3IBA 04/2005 - 10/2002
2	Lipase (Acid Lipase)FDA Link 01/2020 - 12/2019
2	nilotinib FDA Link 10/2019 - 05/2015
2	Small Interfering RNA (siRNA)IBA 01/2019 - 04/2005
2	LigandsIBA 03/2018 - 03/2002
2	Amino Acids FDA Link 04/2011 - 02/2009
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 04/2010 - 01/2004
2	Dasatinib (BMS 354825)FDA Link 05/2009 - 01/2006
2	Complementary DNA (cDNA)IBA 08/2005 - 07/2004
2	bcr-abl Fusion ProteinsIBA 06/2005 - 05/2002
1	AlpelisibIBA 05/2022
1	Temozolomide (Temodar)FDA LinkGeneric 01/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	O-methyl-serine dodecylamide hydrochlorideIBA 01/2022
1	Circulating Tumor DNAIBA 12/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	platelet-derived growth factor C (PDGF-C)IBA 01/2021
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2020
1	asciminibIBA 12/2019
1	Adenosine Triphosphate (ATP)IBA 12/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2019
1	binimetinibIBA 03/2019
1	Mitogen-Activated Protein KinasesIBA 03/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2019
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2018
1	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 01/2016

Therapy/Procedure

46	Therapeutics 10/2022 - 01/2002
8	Drug Therapy (Chemotherapy) 03/2014 - 08/2002
5	Radiotherapy 04/2012 - 07/2006
1	Metastasectomy 10/2022
1	Hepatectomy 01/2022
1	Neoadjuvant Therapy 01/2022
1	Duration of Therapy 11/2021
1	Immunotherapy 01/2019
1	Precision Medicine 05/2017